Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab Maintenance After First-line Chemotherapy in Unresectable or Metastatic Urothelial Cancer
2021-005364-22Phase 2Active
- Sponsor
- SOGUG
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in transitional cell carcinoma (TCC), sponsored by SOGUG. Primary endpoint: Progression Free Survival (PFS). Started Mar 2022; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2021-005364-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005364-22.